FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

Teva Pharmaceuticals Alprostadil Injection 500 mcg/mL Recall

Alprostadil Injection USP 500 mcg/mL, 1 mL Single Dose Vial, 5 vials per Carton, Rx Onl…

Teva Pharmaceuticals USA Inc · Parsippany, NJ

Risk level
Class III
Reported by FDA
Jun 15, 2022
Recall ID
D-0988-2022
Check your lot numberHow we source this data

Summary

Teva Pharmaceuticals recalled Alprostadil Injection 500 mcg/mL starting May 18, 2022. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0988-2022 on Jun 15, 2022. Reason: Failed Impurities/Degradation Specifications; out-of-specification results for impurities obtained during routine stability testing. Status: Terminated.

Why it was recalled

Failed Impurities/Degradation Specifications; out-of-specification results for impurities obtained during routine stability testing

Product description

Alprostadil Injection USP 500 mcg/mL, 1 mL Single Dose Vial, 5 vials per Carton, Rx Only, Carton NDC 0703-1501-02, Distributed by: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, Vial NDC 0703-1501-01

Lot numbers, UPCs & expiration codes

Lot #:100022404, Exp Date 10/2022; Lot #:100023333, Exp Dat 12/2022

Where it was sold

Product was distributed nationwide in the US Market

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0988-2022
Classification
Class III
Status
Terminated
Recall initiated
May 18, 2022
FDA report date
Jun 15, 2022
Quantity
3109 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Teva Pharmaceuticals USA Inc

Original FDA data

Every field from FDA enforcement report D-0988-2022, exactly as published.

Show all FDA fields
City
Parsippany
State
NJ
Status
Terminated
Country
United States
Event ID
90239
Address
400 Interpace Pkwy Bldg A
Code information
Lot #:100022404, Exp Date 10/2022; Lot #:100023333, Exp Dat 12/2022
Postal code
07054-1120
Report date
Jun 15, 2022
Product type
Drugs
Recall number
D-0988-2022
Classification
Class III
Recalling firm
Teva Pharmaceuticals USA Inc
Product quantity
3109 cartons
Termination date
Dec 8, 2023
Reason for recall
Failed Impurities/Degradation Specifications; out-of-specification results for impurities obtained during routine stability testing
Voluntary / mandated
Voluntary: Firm initiated
Product description
Alprostadil Injection USP 500 mcg/mL, 1 mL Single Dose Vial, 5 vials per Carton, Rx Only, Carton NDC 0703-1501-02, Distributed by: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, Vial NDC 0703-1501-01
Distribution pattern
Product was distributed nationwide in the US Market
Recall initiation date
May 18, 2022
Initial firm notification
Letter
Center classification date
Jun 7, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0988-2022, published Jun 15, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls